(2-氧代-吡咯烷-1-基)-乙酸 | 53934-76-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2-氧代-吡咯烷-1-基)-乙酸
• 中文别名: (2-氧代-1-吡咯烷)乙酸
• 英文名称: 2-oxo-1-pyrrolidineacetic acid
• 英文别名: N-(2-pyrrolidone)-2-acetic acid；(2-oxopyrrolidin-1-yl)acetic acid；2-(2-oxopyrrolidin-1-yl)acetic acid
• CAS: 53934-76-2
• 化学式: C₆H₉NO₃
• mdl: MFCD00962836
• 分子量: 143.142
• InChiKey: JGPIWNNFLKDTSR-UHFFFAOYSA-N

物化性质

• 熔点：
  143℃ (benzene )
• 沸点：
  379.1±25.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（少量溶解）、乙酸乙酯（少量，加热）、甲醇（少量溶解）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (2-Oxo-pyrrolidin-1-yl)-acetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (2-Oxo-pyrrolidin-1-yl)-acetic acid
CAS number: 53934-76-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9NO3
Molecular weight: 143.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-氧代-吡咯烷-1-基)-乙酸 在 盐酸 、 potassium tert-butylate 、 sodium carbonate 作用下， 以 水 、 甲苯 为溶剂， 反应 33.5h， 生成 3-氧代哌啶-1-羧酸乙酯
  参考文献：
  名称：

  Specific enolates from .alpha.-amino ketones

  摘要：

  DOI：

  10.1021/jo01300a009
• 作为产物：
  描述：

  N-乙酰甘氨酸 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 (2-氧代-吡咯烷-1-基)-乙酸
  参考文献：
  名称：

  WO2006/138350

  摘要：

  公开号：
• 作为试剂：
  描述：

  2-(4-aminophenyl)-4-hydroxy-5-pyrimidine carboxylic acid 、 2-chloro-1-methylpyridinium sulfate 在 三乙胺 作用下， 以 dichloromethane.* 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 (2-氧代-吡咯烷-1-基)-乙酸 为溶剂， 生成 2-[4-[(2-oxo-1-pyrrolidinyl)acetylamino]phenyl]-4-hydroxy-5-pyrimidine carboxylic acid
  参考文献：
  名称：

  Novel antibacterial amide compounds and process means for producing the

  摘要：

  提供了一种具有广谱抗菌效用的新型有机酰胺化合物，该化合物为N-[2-[(酰胺基酰胺基或氨基酰胺基)苯基]-4-羟基-5-嘧啶基甲酰] 青霉素化合物，其制备方法包括(a)将适当青霉素的游离氨基酸或其酸盐或硅化衍生物或其复合物与相应的N-2-[(酰胺基酰胺基或氨基酰胺基)苯基]-4-羟基-5-嘧啶羧酸的反应衍生物反应，或(b)将6-氨基青霉素酸的游离氨基酸或相关化合物或其酸盐或硅化衍生物与相应的D-N-[2-[(酰胺基酰胺基或氨基酰胺基)苯基]-4-羟基-5-嘧啶基甲酰]-2-取代甘氨酸的反应衍生物反应。还公开了含有这些化合物的药物组合物以及使用这些组合物治疗感染的方法。

  公开号：

  US04267180A1

文献信息

• Photoredox Catalysis: 1,4-Conjugate Addition of <i>N</i>-Methyl Radicals to Electron-Deficient Olefins via Decarboxylation of <i>N</i>-Substituted Acetic Acids
  作者：Lakshmaiah Gingipalli、Jeffrey Boerth、David Emmons、Tyler Grebe、Holia Hatoum-Mokdad、Bo Peng、Li Sha、Sharon Tentarelli、Haixia Wang、Ye Wu、XiaoLan Zheng、Scott Edmondson、Ariamala Gopalsamy

  DOI：10.1021/acs.orglett.0c00873

  日期：2020.5.1

  In this report, we describe a new photoredox catalyzed 1,4-conjugate addition of N-substituted acetic acids to electron-deficient olefins via decarboxylative C-C bond formation. This C-C bond formation occurred under mild conditions enabled by visible light irradiation. This transformation facilitated the synthesis of biologically relevant N-substituted heterocyclic structural motifs not readily accessible

  在本报告中，我们描述了一种新的光氧化还原催化 1,4-共轭加成 N-取代的乙酸通过脱羧 CC 键形成缺电子烯烃。这种CC键形成发生在可见光照射的温和条件下。这种转化促进了其他方法不易获得的生物学相关的 N 取代杂环结构基序的合成。CC键形成方案应用于弱亲核杂环，如吲哚、吲唑、咪唑和环状酰胺，以形成功能化的药物样小分子。
• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYLPYRROLIDINES EN TANT QU'AGONISTES DE RÉCEPTEUR BÊTA-3-ADRÉNERGIQUE
  申请人：MERCK & CO INC

  公开号：WO2009123870A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式I的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• [EN] FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS D'IL-17
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2019138017A1

  公开（公告）日：2019-07-18

  A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

  一系列替代的融合双环咪唑衍生物，包括苯并咪唑衍生物及其类似物，作为强效的人IL-17活性调节剂，因此在治疗和/或预防各种人类疾病，包括炎症性和自身免疫性疾病方面具有益处。
• [EN] ARYL AMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ARYLAMIDE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015006100A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• [EN] C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY<br/>[FR] TRITERPÉNOÏDES MODIFIÉS EN C-17 ET C-3 PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE LA MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012106190A1

  公开（公告）日：2012-08-09

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已列出。具体来说，提供了具有独特抗病毒活性的C-17和C-3修饰三萜类化合物，作为HIV成熟抑制剂，如公式I、II和III所代表的化合物。这些化合物对治疗HIV和艾滋病有用。